POS-328 THE BURDEN OF HYPERKALEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A REPORT FROM THE DISCOVER CKD RETROSPECTIVE COHORT

• G. JAMES,
• J.J. Carrero,
• S. Kumar,
• S. Fishbane,
• E. Wittbrodt,
• E. Kanda,
• K. Hedman,
• N. Kashihara,
• M. Kosiborod,
• M. Lainscak,
• C. Lam,
• C. Pollock,
• P. Stenvinkel,
• D.C. Wheeler,
• R. Pecoits-Filho

Affiliations

G. JAMES

AstraZeneca, None, Cambridge, United Kingdom

J.J. Carrero

Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden

S. Kumar

AstraZeneca, None, Gaithersburg, United States

S. Fishbane

Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Division of Nephrology, Hempstead, United States

E. Wittbrodt

AstraZeneca, None, Gaithersburg, United States

E. Kanda

Kawasaki Medical School, None, Kurashiki, Japan

K. Hedman

AstraZeneca, None, Gothenburg, Sweden

N. Kashihara

Kawasaki Medical School, None, Kurashiki, Japan

M. Kosiborod

Saint Luke's Mid America Heart Institute- University of Missouri-Kansas City, None, Kansas City, United States

M. Lainscak

Faculty of Medicine- University of Ljubljana, None, Ljubljana, Slovenia

C. Lam

National Heart Centre, None, Singapore, Singapore; Duke-NUS Medical School, None, Singapore, Singapore

C. Pollock

Kolling Institute- Royal North Shore Hospital- University of Sydney, None, Sydney, Australia

P. Stenvinkel

Karolinska University Hospital- Karolinska Institutet, Division of Renal Medicine, Stockholm, Sweden

D.C. Wheeler

University College London, Department of Renal Medicine, London, United Kingdom

R. Pecoits-Filho

School of Medicine- Pontifícia Universidade Católica do Paraná, None, Curitiba, Brazil; Arbor Research Collaborative for Health, None, Ann Arbor, United States